Clinical Immunology and Immunopathology
Volume 9, Issue 4, April 1978, Pages 443-453
Smooth muscle antibodies of actin and “non-actin” specificity
References (31)
- et al.
Lancet
(1972) - et al.
Lancet
(1966) - et al.
J. Biol. Chem.
(1971) - et al.
Cell
(1976) - et al.
Clin. Immunol. Immunopathol.
(1977) - et al.
Lancet
(1965) - et al.
Brit. Med. J.
(1971) - et al.
Int. J. Cancer
(1977) - et al.
Brit. Med. J.
(1970) - et al.
Brit. Med. J.
(1973)
J. Pathol.
(1973)
Clin. Exp. Immunol.
(1975)
Clin. Exp. Immunol.
(1975)
Acta Virol.
(1976)
Clin. Exp. Immunol.
(1976)
Cited by (28)
The evolving potential of precision medicine in the management of autoimmune liver disease
2021, Precision Medicine and Artificial Intelligence: The Perfect Fit for AutoimmunityThe clinical usage and definition of autoantibodies in immune-mediated liver disease: A comprehensive overview
2018, Journal of AutoimmunityCitation Excerpt :The molecular target antigen of SMA remains to be defined. Early studies suggest that AIH-1-specific VGT-positive sera target different antigens as compared to non-AIH-1-specific V-positive SMA sera [72–75]. This is also suggested by the different staining pattern at IIF.
Clinical significance of autoantibodies in autoimmune hepatitis
2013, Journal of AutoimmunityCitation Excerpt :More specifically, the use of vinblastine-arrested cultured fibroblasts as a substrate led to the demonstration that AIH-1-specific SMA VGT-positive sera stain predominantly the microfilaments. In contrast, non-AIH-1 SMA V-positive sera react with nonactin-containing intermediate filaments [28–30]. The AIH-1-specific target of SMA responsible for the VGT pattern remains elusive [31].
Copyright © 1978 Published by Elsevier Inc.